Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Rochester, Minnesota

Cancer biologic therapy trials in Rochester, MN

39 cancer biologic therapy studies are recruiting participants at sites in Rochester as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Rochester at a glance

  • 39 studies are recruiting at a site in Rochester.
  • By phase: Phase 1 (7), Phase 1/2 (4), Phase 2 (13), Phase 2/3 (2), Phase 3 (13).
  • By sponsor: university, hospital or other (19), industry (12), government (8).
  • By research area: Lymphoma (17), Lung Cancer (9), Breast Cancer (7), Melanoma (3), Prostate Cancer (2), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Rochester

Basic details from each study's public record (the 30 most recently updated of 39). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT05564377 · updated
  2. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06876714 · updated
  3. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BriaCell Therapeutics Corporation
    Study site
    Mayo Clinic-Comprehensive Cancer Center-Breast Clinic
    Registry record
    NCT06072612 · updated
  4. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT05812807 · updated
  5. A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT04521764 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Rochester, MN on ClinicalTrials.gov.

Lung cancer studies recruiting in Rochester

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT04267848 · updated
  2. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic - Rochester ( Site 0073)
    Registry record
    NCT06312137 · updated
  3. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic - Rochester ( Site 0148)
    Registry record
    NCT06170788 · updated
  4. Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06918132 · updated
  5. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06116682 · updated
  6. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06616584 · updated
  7. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Mayo Clinic-Rochester
    Registry record
    NCT06892548 · updated
  8. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT05624996 · updated
  9. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Rochester, MN on ClinicalTrials.gov.

Prostate cancer studies recruiting in Rochester

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT03866382 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    Mayo Clinic
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Rochester, MN on ClinicalTrials.gov.

Melanoma studies recruiting in Rochester

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT05136196 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Mayo Clinic
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Rochester, MN on ClinicalTrials.gov.

Lymphoma studies recruiting in Rochester

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06337318 · updated
  2. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT04840602 · updated
  3. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT05675410 · updated
  4. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Mayo Clinic Rochester
    Registry record
    NCT07188558 · updated
  5. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT03150693 · updated
  6. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06124157 · updated
  7. Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT03516617 · updated
  8. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    • Phase 1/2
    • Ages 13 to 90
    • All sexes
    Sponsor
    Vironexis Biotherapeutics Inc.
    Study site
    Mayo Clinic, Clinical Trials Referral Office
    Registry record
    NCT06533579 · updated
  9. Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT06834373 · updated
  10. Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT03418038 · updated
  11. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Rochester, MN on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Rochester

  1. BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Mayo Clinic in Rochester
    Registry record
    NCT07226856 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Rochester, MN on ClinicalTrials.gov.

Ask about studies near Rochester

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Minnesota

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call